BioXcel Therapeutics (NASDAQ:BTAI) Earns Buy Rating from Analysts at Rodman & Renshaw
Rodman & Renshaw began coverage on shares of BioXcel Therapeutics (NASDAQ:BTAI – Free Report) in a report issued on Wednesday morning,Benzinga reports. The firm issued a buy rating and a $65.00 target price on the stock. BTAI has been the topic of several other research reports. Bank of America reaffirmed an “underperform” rating and set […]
Rodman & Renshaw began coverage on shares of BioXcel Therapeutics (NASDAQ:BTAI – Free Report) in a report issued on Wednesday morning,Benzinga reports. The firm issued a buy rating and a $65.00 target price on the stock. BTAI has been the topic of several other research reports. Bank of America reaffirmed an “underperform” rating and set […]
